

Applicants respond to the Official Action dated March 25, 2009 (Paper No. 20090317) in the above-identified application, as follows.

a.) REMARKS


In the outstanding Office Action, the Examiner required that Applicants elect for prosecution one of the inventions of:

Group I (Claims 1-11 and 17-20, drawn to a prophylactic and/or therapeutic agent.

Group II (Claims 12 and 14-15), drawn to a method of treating fibromyalgia.

In response, Applicants hereby elect to prosecute the invention of Group II, namely Claims 12 and 14-15.

The Examiner is further requiring that Applicants select a species for search, see page 5 of the Office Action. In this regard, Applicants note the Examiner refers only to Group I therein. Accordingly, no response is required. Nonetheless, in case this omission was oversight, to expedite prosecution Applicants hereby identify compound 2 listed in Table 1 (at specification page 41) as such single species.



**Compound 2**

Entry hereof is earnestly solicited.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our below listed address.

Respectfully submitted,

/Lawrence S. Perry/  
Lawrence S. Perry  
Attorney for Applicants  
Registration No. 31,865

FITZPATRICK, CELLA, HARPER & SCINTO  
30 Rockefeller Plaza  
New York, New York 10112-3801  
Facsimile: (212) 218-2200

LSP\ac

FCIS\_WS 3292527\_1.DOC